221 related articles for article (PubMed ID: 16916424)
21. Schizophrenia, antipsychotics and metabolic disease.
Reynolds GP
J Psychopharmacol; 2007 Jun; 21(4):355-6. PubMed ID: 17656424
[No Abstract] [Full Text] [Related]
22. [Current views on the metabolic syndrome and the effects of antipsychotic drugs].
Fodor M
Psychiatr Hung; 2011; 26(3):196-200. PubMed ID: 21799222
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics.
Kozumplik O; Uzun S; Jakovljević M
Psychiatr Danub; 2010 Mar; 22(1):69-74. PubMed ID: 20305594
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular risks of atypical antipsychotic drug treatment.
Drici MD; Priori S
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
[TBL] [Abstract][Full Text] [Related]
25. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.
Mulder H; Franke B; van der-Beek van der AA; Arends J; Wilmink FW; Scheffer H; Egberts AC
J Clin Psychopharmacol; 2007 Aug; 27(4):338-43. PubMed ID: 17632216
[TBL] [Abstract][Full Text] [Related]
26. Side effects as influencers of treatment outcome.
Sharif Z
J Clin Psychiatry; 2008; 69 Suppl 3():38-43. PubMed ID: 18533761
[TBL] [Abstract][Full Text] [Related]
27. Weight gain and first-generation antipsychotics: experience from a developing country.
Yoon CK
J Clin Psychopharmacol; 2008 Oct; 28(5):574-6. PubMed ID: 18794660
[No Abstract] [Full Text] [Related]
28. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.
Barnett AH; Mackin P; Chaudhry I; Farooqi A; Gadsby R; Heald A; Hill J; Millar H; Peveler R; Rees A; Singh V; Taylor D; Vora J; Jones PB
J Psychopharmacol; 2007 Jun; 21(4):357-73. PubMed ID: 17656425
[TBL] [Abstract][Full Text] [Related]
29. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 1():28-33. PubMed ID: 17286525
[TBL] [Abstract][Full Text] [Related]
30. Amisulpride-associated acute onset of metabolic syndrome in a schizophrenia patient.
Chang CK; Hung GC
Psychiatry Clin Neurosci; 2013 Feb; 67(2):131. PubMed ID: 23438173
[No Abstract] [Full Text] [Related]
31. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
32. Schizophrenia, obesity, and antipsychotic medications: what can we do?
Citrome L; Vreeland B
Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
[TBL] [Abstract][Full Text] [Related]
33. An analysis of popular weight loss diet types in relation to metabolic syndrome therapeutic guidelines.
McClendon DA; Dunbar SB; Clark PC; Coverson DL
Medsurg Nurs; 2010; 19(1):17-24. PubMed ID: 20336980
[TBL] [Abstract][Full Text] [Related]
34. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
[TBL] [Abstract][Full Text] [Related]
35. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
Tirupati S; Chua LE
Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
[TBL] [Abstract][Full Text] [Related]
36. [Schizophrenia: adverse effects of atypical neuroleptics].
Bettina Polk B
Med Monatsschr Pharm; 2003 Feb; 26(2):57-9. PubMed ID: 12619525
[No Abstract] [Full Text] [Related]
37. [The metabolic syndrome and antipsychotics in children and adolescents].
Dori N; Green T
Harefuah; 2011 Oct; 150(10):791-6, 814, 813. PubMed ID: 22111125
[TBL] [Abstract][Full Text] [Related]
38. Physical health and schizophrenia.
Mitchell AJ; Malone D
Curr Opin Psychiatry; 2006 Jul; 19(4):432-7. PubMed ID: 16721177
[TBL] [Abstract][Full Text] [Related]
39. Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.
Park T; Usher K; Foster K
Int J Ment Health Nurs; 2011 Dec; 20(6):428-37. PubMed ID: 21564457
[TBL] [Abstract][Full Text] [Related]
40. Follow-up interventions in persons with schizophrenia and metabolic syndrome.
Kølbæk P; Schiöth E; Aagaard J; Munk-Jørgensen P
Aust N Z J Psychiatry; 2014 Nov; 48(11):1059-60. PubMed ID: 25277542
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
